Abstract
Here we investigated whether the cellular accumulation of p53 protein caused by over-expression of small ubiquitin-related modifier-1 (SUMO-1) could be used as a predictive marker for prognosis in colon cancer. We detected SUMO-1 and p53 protein levels in 46 cases of colon cancer and adjacent tissues by immunohistochemistry and found that SUMO-1 was expressed at much higher levels in colon cancer compared with that in normal colon tissue. Immunoprecipitation and Western blot analysis revealed that the tumor suppressor p53 was present predominantly in the sumoylated rather than the non-sumoylated form in the colon cancer cell lines. A small interfering RNA targeted to SUMO-1 mRNA sequences was used to observe the levels of the p53 protein. Patients who showed high dual expressions of SUMO-1 and p53 tended to experience metastasis more frequently. These results suggest that the cellular accumulation of p53 protein caused by over-expression of SUMO-1 may be involved in tumor aggressiveness. Multivariate analysis confirmed that the high dual expression of SUMO-1 and p53 was an independent factor for evaluating prognosis. SUMO-1 may be useful as a novel target for therapy in colon cancer as well as a clinical indicator for tumor aggressiveness.
Similar content being viewed by others
References
Nasif, W. A., Lotfy, M., El-Sayed, I. H., El-Kenawy, Ael-M., El-Shahat, M., & El-Hak, N. G. (2006). Implications of CEA and p53 overexpression in the poor prognosis of colorectal cancer. Medical Oncology, 23(2), 237–244.
Vousden, K. H., & Lane, D. P. (2007). p53 in health and disease. Nature Reviews Molecular Cell Biology, 8(4), 275–283.
Yang, X. J. (2005). Multisite protein modification and intramolecular signaling. Oncogene, 24(10), 1653–1662.
Hochstrasser, M. (2000). Evolution and function of ubiquitin-like protein conjugation systems. Nature Cell Biology, 2, E153–E157.
Yeh, E. T., Gong, L., & Kamitani, T. (2000). Ubiquitin-like proteins: New wines in new bottles. Gene, 248, 1–14.
Melchior, F. (2000). SUMO—Nonclassical ubiquitin. Annual Review of Cell and Developmental Biology, 16, 591–626.
Muller, S., Hoege, C., Pyrowolakis, G., & Jentsch, S. (2001). SUMO, ubiquitin’s mysterious cousin. Nature Reviews Molecular Cell Biology, 2(3), 202–210.
Hay, R. T. (2005). SUMO: A history of modification. Molecular Cell, 18(1), 1–12.
Muller, S., Ledl, A., & Schmidt, D. (2004). SUMO: A regulator of gene expression and genome integrity. Oncogene, 23, 1998–2008.
Gill, G. (2005). Something about SUMO inhibits transcription. Current Opinion in Genetics & Development, 15, 536–541.
Alarcon-Vargas, D., & Ronai, Z. (2002). SUMO in cancer-wrestlers wanted. Cancer Biology & Therapy, 1, 237–242.
Seeler, J. S., & Dejean, A. (2003). Nuclear and unclear functions of SUMO. Nature Reviews Molecular Cell Biology, 4, 690–699.
Johnson, E. S. (2004). Protein modification by SUMO. Annual Review of Biochemistry, 73, 355–382.
Girdwood, D. W., Tatham, M. H., & Hay, R. T. (2004). SUMO and transcriptional regulation. Seminars in Cell & Developmental Biology, 15(2), 201–210.
Sternsdorf, T., Jensen, K., & Will, H. (1997). Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. Journal of Cell Biology, 139, 1621–1634.
Bies, J., Markus, J., & Wolff, L. (2002). Covalent attachment of the SUMO-1 protein to the negative regulatory domain of the c-Myb transcription factor modifies its stability and transactivation capacity. Journal of Biological Chemistry, 277, 8999–9009.
Muller, S., Berger, M., Lehembre, F., Seeler, J. S., Haupt, Y., & Dejean, A. (2000). c-Jun and p53 activity is modulated by SUMO-1 modification. Journal of Biological Chemistry, 275(18), 13321–13329.
Katayama, A., Ogino, T., Bandoh, N., Takahara, M., Kishibe, K., Nonaka, S., et al. (2007). Overexpression of small ubiquitin-related modifier-1 and sumoylated Mdm2 in oral squamous cell carcinoma: Possible involvement in tumor proliferation and prognosis. International Journal of Oncology, 31, 517–524.
Muller, S., Matunis, M. J., & Dejean, A. (1998). Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO Journal, 17, 61–70.
Buschmann, T., Fuchs, S. Y., Lee, C. G., Pan, Z. Q., & Ronai, Z. (2000). SUMO-1 modification of mdm2 prevents its self-ubiquitination and increases mdm2 ability to ubiquitinate p53. Cell, 101, 753–762.
Schmidt, D., & Muller, S. (2002). Members of the PIAS family acts as SUMO ligases for c-Jun and p53 and repress p53 activity. Proceedings of the National Academy of Sciences of the United States of America, 99, 2872–2877.
Huang, Y. P., Wu, G., Guo, Z., Osada, M., Fomenkov, T., Park, H. L., et al. (2004). Altered sumoylation of p63 contributes to the split-hand/foot malformation phenotype. Cell Cycle, 3, 1587–1596.
Bischof, O., Schwamborn, K., Martin, N., Werner, A., Sustmann, C., Grosschedl, R., et al. (2006). The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Molecular Cell, 22(6), 783–794.
Ghosh, M., Weghorst, K., & Berberich, S. J. (2005). MdmX inhibits ARF mediated Mdm2 sumoylation. Cell Cycle, 4, 604–608.
Lan, Y. T., Chang, S. C., Li, A. F., Lin, T. C., Chen, W. S., Jiang, J. K., et al. (2007). p53 protein accumulation as a prognostic marker in sporadic colorectal cancer. International Journal of Colorectal Disease, 22(5), 499–506.
Chang, S. C., Lin, J. K., Lin, T. C., & Liang, W. Y. (2005). Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. International Journal of Oncology, 26(1), 65–75.
Acknowledgments
This work was supported by grant support for Scientific Research from Jiangsu Province, China (BK2006243), and by a grant from the National Science Foundation, China (C30771039).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Zhang, H., Kuai, X., Ji, Z. et al. Over-Expression of Small Ubiquitin-Related Modifier-1 and Sumoylated p53 in Colon Cancer. Cell Biochem Biophys 67, 1081–1087 (2013). https://doi.org/10.1007/s12013-013-9612-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12013-013-9612-x